Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 6, 2012, Pages 535-543

  Cai, Ying ^a   Liu, Xinran ^a   Huang, Weidan ^a   Zhang, Kangjian ^a   Liu, Xin Yuan ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

apoptosis; cancer therapy; cancer targeting dual gene viro therapy (CTGVT DG); Mda 7 IL 24; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 24; INTERLEUKIN DERIVATIVE; INTERLEUKIN-24; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL STRAIN HEK293; CELL SURVIVAL; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE THERAPY; GENETICS; HUMAN; LIVER CELL CARCINOMA; MALE; METHODOLOGY; MOUSE; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; GENE THERAPY; HEK293 CELLS; HUMANS; INTERLEUKINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 84861903658     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gms031     Document Type: Article

References (34)

1. Liu XY. A new anticancer strategy-gene-virotherapy therapy of cancer. Chin J Cancer Biother 2001, 8:1.
2. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY and Qian QJ, et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003, 13:481-489.
3. Evans J. Recent deal highlights hopes for cancer-killing viruses. Nat Med 2011, 17:268-269.
4. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ and Nieva J, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477:99-102.
5. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L and Wang Y, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005, 16:845-858.
6. Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W and Wang Y, et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther 2006, 13:1011-1022.
7. Zhang Y, Gu J, Zhao L, He L, Qian W, Wang J and Wang Y, et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res 2006, 66:4291-4298.
8. Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R and Gu J, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004, 39:1371-1381.
9. Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA and Reed JC, et al. Bcl-2 and Bcl-x (L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 2003, 22:8758-8773.
10. Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC and Fisher PB. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 2002, 21:708-718.
11. Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC and Goldstein NI, et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci USA 1998, 95:14400-14405.
12. Saeki T, Mhashilkar A, Chada S, Branch C, Roth JA and Ramesh R. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Ther 2000, 7:2051-2057.
13. Patani N, Douglas-Jones A, Mansel R, Jiang W and Mokbel K. Tumour suppressor function of MDA-7/IL-24 in human breast cancer. Cancer Cell Int 2010, 10:29.
14. Sauane M, Su ZZ, Gupta P, Lebedeva IV, Dent P, Sarkar D and Fisher PB. Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proc Natl Acad Sci USA 2008, 105:9763-9768.
15. Su Z, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, Reed JC and Dent P, et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 2001, 98:10332-10337.
16. Su ZZ, Lebedeva IV, Sarkar D, Gopalkrishnan RV, Sauane M, Sigmon C and Yacoub A, et al. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 2003, 22:1164-1180.
17. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK and Sutherland GR, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
18. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA and Blackie C, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162.
19. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M and Chin W, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163.
20. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA and Curley SA, et al. Antitumor activity and bystander effects of the tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001, 61:3330-3338.
21. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL and Ross BD, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000, 97:1754-1759.
22. Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F and Xu R. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005, 65:1687-1692.
23. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620.
24. Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA and Fang B. Targeted expression of green fluorescent protein/tumor necrosis factorrelated apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 2002, 62:3620-3625.
25. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: The National Academies Press, 1996.
26. Fisher PB. Is mda-7/IL-24 a 'magic bullet' for cancer? Cancer Res 2005, 65:10128-10138.
27. Yew PR and Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992, 357:82-85.
28. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D and Kaelin WG, et al. Degradation of p53 by adenovirus E4 or f6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 2001, 15:3104-3117.
29. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A and Boyle L, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004, 6:611-623.
30. O'Shea CC, Soria C, Bagus B and McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005, 8:61-74.
31. Soria C, Estermann FE, Espantman KC and O'Shea CC. Heterochromatin silencing of p53 target genes by a small viral protein. Nature 2010, 466:1076-1081.
32. Zhang Z, Huang Y, Newman K, Gu J, Zhang X, Wu H and Zhao M, et al. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factorrelated apoptosis-inducing ligand against pancreatic cancer. Clin Cancer Res 2009, 15:5154-5160.
33. Chu L, Gu J, He Z, Xiao T and Liu X. Adenoviral vector expressing CYLD augments antitumor activity of TRAIL by suppression of NF-kappaB survival signaling in hepatocellular carcinoma. Cancer Biol Ther 2006, 5:615-622.
34. Liu XY, Qiu SB, Zou WG, Pei ZF, Gu JF, Luo CX and Ruan HM, et al. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 2005, 11:531-541.